The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3

Cheng, Yueming; Yang, Yan; Wu, Yan-Guang; Wang, Wencheng; Xiao, Lichun; Zhang, Yifan; Tang, Justin; Huang, Yadong; Zhang, Shu; Xiang, Qi

doi:10.3389/fphar.2020.00637

Cited by 9 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The docking of the synthesized compounds were successfully correlated with the three dimensional crystallographic structures of the compound, specifically 1d, as observed against AChE and BuChE, given the in vitro results of 1d structure similarities with the calculated binding affinities of (−12.089 kcal/mol) and (−10.962 kcal/mol), respectively [25]. The compound 1d with chloride substituent on a phenyl ring showed higher enzyme inhibitory potential when compared to other analogs, which was parallel with the previous finding [26].…”

Section: Discussionsupporting

confidence: 84%

Attenuation of Scopolamine-Induced Amnesia via Cholinergic Modulation in Mice by Synthetic Curcumin Analogs

et al. 2022

View full text Add to dashboard Cite

Alzheimer’s disease is an emerging health disorder associated with cognitive decline and memory loss. In this study, six curcumin analogs (1a–1f) were synthesized and screened for in vitro cholinesterase inhibitory potential. On the basis of promising results, they were further investigated for in vivo analysis using elevated plus maze (EPM), Y-maze, and novel object recognition (NOR) behavioral models. The binding mode of the synthesized compounds with the active sites of cholinesterases, and the involvement of the cholinergic system in brain hippocampus was determined. The synthesized curcumin analog 1d (p < 0.001, n = 6), and 1c (p < 0.01, n = 6) showed promising results by decreasing retention time in EPM, significantly increasing % SAP in Y-maze, while significantly (p < 0.001) enhancing the % discrimination index (DI) and the time exploring the novel objects in NORT mice behavioral models. A molecular docking study using MOE software was used for validation of the inhibition of cholinesterase(s). It has been indicated from the current research work that the synthesized curcumin analogs enhanced memory functions in mice models and could be used as valuable therapeutic molecules against neurodegenerative disorders. To determine their exact mechanism of action, further studies are suggested.

show abstract

Section: Discussionsupporting

confidence: 84%

Attenuation of Scopolamine-Induced Amnesia via Cholinergic Modulation in Mice by Synthetic Curcumin Analogs

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The experimental group consisted of 132 mice, whereas the control group consisted of 131 mice, resulting in a total of 263 mice used in the study. Among the included studies, 13 originated in China ( Limin et al, 2007 ; Qi, 2009 ; ZHAO et al, 2010 ; LI et al, 2013 ; Zhang, 2013 ; Huang et al, 2015 ; QI et al, 2015 ; Yang et al, 2015 ; Ye, 2015 ; Roy et al, 2016 ; Zhao et al, 2018 ; MAO et al, 2019 ; Cheng et al, 2020 ). Additionally, three studies were conducted in the United States ( Dorai et al, 2001 ; Khor et al, 2006 ; Barve et al, 2008 ), while one study was conducted in Spain ( Fernández-Martínez et al, 2009 ).…”

Section: Resultsmentioning

confidence: 99%

“…Twelve studies ( Dorai et al, 2001 ; Higgins and Thompson, 2002 ; Khor et al, 2006 ; Limin et al, 2007 ; Fernández-Martínez et al, 2009 ; ZHAO et al, 2010 ; LI et al, 2013 ; Zhang, 2013 ; Hooijmans et al, 2014a ; Huang et al, 2015 ; Yang et al, 2015 ; Ye, 2015 ; Roy et al, 2016 ; Zhao et al, 2018 ; Cheng et al, 2020 ) included in the analysis provided data on the tumor volume. The findings revealed a noteworthy suppressive effect of curcumin on PCa tumor volume in mice compared to that in the control groups (SMD: 1.16, 95% CI: 0.52, 1.80, p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

Application and potential value of curcumin in prostate cancer: a meta-analysis based on animal models

Wang,

Zhang,

Chen

2024

Front. Pharmacol.

View full text Add to dashboard Cite

IntroductionCurcumin is gaining recognition as an agent for cancer chemoprevention and is presently administered to humans. However, the limited number of clinical trials conducted for the treatment of prostate cancer is noteworthy. Animal models serve as valuable tools for enhancing our understanding of disease mechanisms and etiology in humans. The objective of this study was to examine the anti-prostate cancer effects of curcumin in vivo for comprehending its current research status and potential clinical applicability.MethodsOur methodology involved a systematic exploration of animal studies pertaining to curcumin and prostate cancer, as documented in PubMed, Web of Science, Embase, Cochrane Library, CNKI, Wanfang database, Vip database, and SinoMed, up to 03 September 2023. Risk of bias was assessed using the SYRCLE Animal Study Risk of Bias tool. The results were combined using the RevMan 5.3.ResultsA comprehensive analysis was conducted on 17 studies encompassing 263 mouse transplantation tumor models. The findings of this meta-analysis demonstrated that curcumin exhibited a superior inhibitory effect on the volume of prostate cancer tumors in mice compared to the control group (standardized mean difference [SMD]: 1.16, 95% confidence interval [CI]: 0.52, 1.80, p < 0.001). Additionally, curcumin displayed a more effective inhibition of mice prostate cancer tumor weight (SMD: −3.27, 95% CI: −4.70, −1.83, p < 0.001). Furthermore, in terms of tumor inhibition rate, curcumin exhibited greater efficacy (SMD: 0.25, 95% CI: 0.23, 0.27, p < 0.001). Moreover, curcumin more effectively inhibited PCNA mRNA (SMD: −3.11, 95% CI: −4.60, −1.63, p < 0.001) and MMP2 mRNA (SMD: −3.19, 95% CI: 5.85, −0.53, p < 0.001).ConclusionCurcumin exhibited inhibitory properties towards prostate tumor growth and demonstrated a beneficial effect on prostate cancer treatment, thereby offering substantiation for further clinical investigations. It is important to acknowledge that the included animal studies exhibited considerable heterogeneity, primarily because of the limited number of studies included. Consequently, additional randomized controlled trials are required to comprehensively assess the efficacy of curcumin in humans.Systematic Review Registration(https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023464661), identifier (CRD42023464661).

show abstract

“…In addition, H10 was found to have weaker inhibitory activity towards liver CYP3A4, even after long-term administration [64]. H10 was also reported to inhibit the Adione-stimulated growth of prostate cancer cell xenografts established in nude mice [65].…”

Section: Pharmacokinetics Of Different Curcumin Dosage Preparationsmentioning

confidence: 97%

Review of Curcumin and Its Different Formulations: Pharmacokinetics, Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Interactions

Goswami¹,

Saxena²,

Yadav³

et al. 2022

OBM Integr Complement Med

View full text Add to dashboard Cite

Curcumin, the yellow principle of the Indian Turmeric, ‘Haldi’ has recently attracted renewed interest in the field of experimental medicine with pleiotropic activity. This review has emphasized three pharmaceutical studies of interest: the pharmacokinetics, pharmacology, and pharmacodynamics of curcumin. In this review, we attempted to review the general pharmacokinetics profile, pharmacokinetic interactions, and pharmacokinetic-pharmacodynamic interactions of curcumin and its formulations. Different species of turmeric in India, as well as their cultivars, different forms of curcumin, and harvesting methods have also been discussed. Furthermore, pharmacokinetic studies of the interaction of curcumin and its different formulations with efflux transporters such as P-glycoprotein, ABC-transporter protein, multidrug-resistant protein, and cytochrome p450 metabolism enzymes have been broadly explained following data from preclinical and clinical trials reported in the literature. A few interesting chemical interactions between curcumin and its metabolites with the receptor have also been described. The pharmacological activities of curcumin and its related formulations and products have been reviewed in a few targeted disease pathologies of national concern, such as cancer, gastroduodenal disorder, immunodeficiency, liver disease, ophthalmology, diabetes and osteoarthritis among other metabolic diseases, and microbial and viral infections. The pharmacodynamics of curcumin, especially regarding the potassium/calcium ion channel pathway, apoptosis, calcium signaling pathway, endoplasmic reticulum stress, and other intracellular signaling pathways, have been documented. Lastly, the use of curcumin as a cosmetic and the value chain analysis of turmeric products, as well as curcumin, have also been placed appropriately. A total of 174 publications were reviewed and, overall, this review tried to cover various important therapeutic aspects of curcumin, which can generate new research interest in general.

show abstract

The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3

Cited by 9 publications

References 24 publications

Attenuation of Scopolamine-Induced Amnesia via Cholinergic Modulation in Mice by Synthetic Curcumin Analogs

Attenuation of Scopolamine-Induced Amnesia via Cholinergic Modulation in Mice by Synthetic Curcumin Analogs

Application and potential value of curcumin in prostate cancer: a meta-analysis based on animal models

Review of Curcumin and Its Different Formulations: Pharmacokinetics, Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Interactions

Contact Info

Product

Resources

About